40エピソード

ESMO Open is the European Society for Medical Oncology’s online-only, peer-reviewed Open Access journal, dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research.

ESMO Open talk medicine

    • 科学
    • 3.0 • 1件の評価

ESMO Open is the European Society for Medical Oncology’s online-only, peer-reviewed Open Access journal, dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research.

    ESMO-Magnitude of Clinical Benefit Scale (V1.1) for early breast cancer therapies

    ESMO-Magnitude of Clinical Benefit Scale (V1.1) for early breast cancer therapies

    We evaluated the applicability of the scale and assessed the reasonableness of the generated scores in early breast cancer. Form 1 of the ESMO-MCBS v1.1 provided a generally robust tool for scoring of adjuvant breast cancer studies. Six shortcomings were identified including lack of information regarding acute and long-term toxicity, an inability to grade single arm de-escalation scales and limitations related to grading based on disease free survival (DFS).
    Read the paper on the ESMO Open website: http://dx.doi.org/10.1136/esmoopen-2020-000743

    ESMO-Magnitude of Clinical Benefit Scale of adjuvant colon cancer trials and meta-analyses

    ESMO-Magnitude of Clinical Benefit Scale of adjuvant colon cancer trials and meta-analyses

    Form 1 of the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) serves to grade therapies with curative intent. Form 1 provided very reasonable grading and expert field testers confirmed the reasonableness of generated scores. Exploratory toxicity evaluation and annotation was feasible but problematic given inconsistent toxicity reporting and limited results of late toxicity. Moreover, the experts identified the inability of crediting improved convenience in non-inferiority trials as a shortcoming. Future revisions of Form 1 of the ESMO-MCBS will be cognoscente of these findings.
    Read the paper on the ESMO Open website: http://dx.doi.org/10.1136/esmoopen-2020-000681

    Adjuvant and neoadjuvant therapies in melanoma

    Adjuvant and neoadjuvant therapies in melanoma

    The therapeutic landscape in melanoma is evolving rapidly. In this podcast, Jonathan Lim (a member of the ESMO Young Oncologists Committee) interviews Dr Teresa Amaral (the current chair of the ESMO Young Oncologists Committee and an expert in melanoma) for an update on the current practice and advances in adjuvant and neoadjuvant therapies in melanoma.
    Dr Amaral summarises key practice-changing studies which have established the current recommendations in this field, including CheckMate 238, KEYNOTE 054, COMBI-AD, Combi-Neo, NeoCombi and opACIN-neo. We also deliberated on the toxicity profile of these therapies, and currently available evidence of neoadjuvant versus adjuvant therapies. Finally, we addressed how COVID-19 has affected the delivery of adjuvant and neoadjuvant therapies in patients with melanoma.

    Further reading:
    CheckMate 238 – https://doi.org/10.1056/NEJMoa1709030
    KEYNOTE 054 – https://doi.org/10.1056/NEJMoa1802357
    EORTC18071 – https://doi.org/10.1016/S1470-2045(15)70122-1
    Mixture-Cure Modeling in CheckMate 238 – https://doi.org/10.1093/annonc/mdz255
    COMBI-AD – https://doi.org/10.1056/NEJMoa1708539
    Combi-Neo – https://doi.org/10.1016/S1470-2045(18)30015-9
    NeoCombi – https://doi.org/10.1016/S1470-2045(19)30331-6
    OpACIN-neo – https://doi.org/10.1016/S1470-2045(19)30151-2

    Emerging targets in cancer immunotherapy

    Emerging targets in cancer immunotherapy

    The advent of cancer immunotherapy has radically changed the field of oncology by improving the way many malignancies, including several aggressive and orphan diseases, are being treated with subsequent major improvement of patients’ prognosis. The first crucial and successful step in the field was the development of agents able to inactivate inhibitory immune receptors resulting in a subsequent increased anti-tumor response. Among them, antibodies blocking CTLA-4 (ipilimumab) and PD-1/PD-L1 (nivolumab, pembrolizumab, atezolizumab and durvalumab) are already widely available in clinical practice. More recently, to further improve the ability of the immune system to eradicate cancer cells, several other stimulatory or inhibitory molecules have been recognized as possible targets. ESMO Open has launched a special series of mini-reviews aiming to provide an update of the most interesting and upcoming targets in cancer immunotherapy including LAG3, TIM3, CD40, B7x, OX40, ICOS, VISTA, CD27, GITR and neoantigens. All these mini-reviews contain information on biological background (i.e. what the target is, where it is expressed and what is the physiological role as well as the expected effect when targeting it), drugs under development for targeting that specific molecule as well as current on-going clinical trials with targeted agents (including those in combination with other immune checkpoint inhibitors).
    In this podcast, Anna Berghof talks to Matteo Lambertini - Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
    Read the Abstract: https://esmoopen.bmj.com/content/4/Suppl_3/e000795

    News in breast cancer 2019

    News in breast cancer 2019

    Anna Berghof talks to Matteo Lambertini - Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
    The year 2019 has brought relevant new biological and clinical evidence to further improve the care of breast cancer patients.
    Regarding biological knowledge, in addition to the many important steps forward in enhancing the understanding of several aspects related to tumor biology and treatment resistance, more predictive biomarkers have entered clinical use. In addition to knowing the status of hormone receptors and HER2, other biomarkers should now be tested in different disease subtypes and clinical situations including PD-L1, PIK3CA mutations and germline BRCA mutations.
    The clinical management of breast cancer patients has also significantly changed. Important evidence has become available to further personalize the choices of the best chemotherapy, endocrine treatment and targeted therapy approaches in both the advanced and early settings. Importantly, for patients with advanced breast cancer including those treated in the first-line setting, overall survival improvements have finally been observed in all disease subtypes thanks to the availability of more effective targeted agents.
    Many upcoming translational and clinical data are expected in 2020 with a great promise of further changing clinical practice in the breast cancer field. This is the case also for the triple-negative subtype where more effective and targeted treatment options beyond chemotherapy are expected to enter clinical use and improve patients’ outcomes and quality of life.
    Read the Abstract on the ESMO Open website: https://esmoopen.bmj.com/content/5/3/e000794

    Cancer care during the spread of Covid-19 in Italy: a young oncologist's perspective

    Cancer care during the spread of Covid-19 in Italy: a young oncologist's perspective

    The Covid-19 pandemic is currently active all over Europe and especially in Italy. In this podcast Anna Berghof discusses with Matteo Lambertini - Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy - the difficulties of cancer treatment during this pandemic.
    Read the editorial: https://esmoopen.bmj.com/content/5/2/e000759

カスタマーレビュー

3.0/5
1件の評価

1件の評価

科学のトップPodcast

他のリスナーはこちらのサブスクリプションにも登録しています